Clinical Trial Detail

NCT ID NCT04277442
Title Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

Therapies

Decitabine + Nivolumab + Venetoclax

Age Groups: adult senior

No variant requirements are available.